Loading…
BeOne Medicines AG is projected to rise to $468.47 by 2027, a +42% move from its current price of $330.46. ONC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/29/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 31 | $325.88 | $330.68 | $335.55 | +0.07% |
| Aug 1 | $324.12 | $330.90 | $337.81 | +0.13% |
| Aug 2 | $322.84 | $331.12 | $339.61 | +0.20% |
| Aug 3 | $321.79 | $331.33 | $341.17 | +0.26% |
| Aug 4 | $320.89 | $331.55 | $342.57 | +0.33% |
| Aug 5 | $320.10 | $331.77 | $343.87 | +0.40% |
| Aug 6 | $319.39 | $331.99 | $345.09 | +0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $319.39 | $331.99 | $345.09 | +0.46% |
| Week 2 | $315.77 | $333.53 | $352.29 | +0.93% |
| Week 3 | $313.36 | $335.08 | $358.30 | +1.40% |
| Week 4 | $311.57 | $336.63 | $363.71 | +1.87% |
| Week 5 | $310.17 | $338.19 | $368.75 | +2.34% |
| Week 6 | $309.04 | $339.76 | $373.53 | +2.81% |
| Week 7 | $308.13 | $341.34 | $378.12 | +3.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BeOne Medicines AG is an oncology company that engages in discovering and developing treatments for cancer patients across the United States, China, Europe, and international markets.
Its commercial-stage products include BRUKINSA, TEVIMBRA, SYLVANT, BAITUOWEI, and PARTRUVIX. The company has clinical-stage programs and partnerships with Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis.
BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland. It formerly operated under the name BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025.
BeOne Medicines AG (ONC) operates in the Healthcare sector. The stock trades at a current price of $311.26 and has a market capitalization of $32.29B, with a market position reflected by a rank of 435.
The near-term outlook shows mixed momentum with a neutral stance in 2026 and bullish momentum from 2027 onward, along with rising price expectations through 2050. The forecast implies a 2026 average price of $311.26 and an eventual move to $679.81 by 2030, climbing further to $3,623.04 by 2050, with ROIs advancing from 0% in 2026 to 1064% in 2050.
Overall, current price and the 2026 neutral footing serve as a baseline for a substantial long-term upside reflected in the multi-year forecast, continuing a bullish trajectory into 2030, 2040, and 2050.
A major floor 27.1% below — a decisive break under it would weaken the trend.
The nearest floor, 21.2% below — buyers have tended to step in here.
Price is pressing into resistance (1.1% away) — a breakout level to watch.
A major ceiling 11.7% above — clearing it would confirm fresh momentum.
Key ONC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ONC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $323.44 | Buy | $322.94 | Buy |
| MA 10 | $317.50 | Buy | $317.74 | Buy |
| MA 20 | $308.21 | Buy | $309.04 | Buy |
| MA 50 | $292.35 | Buy | $300.15 | Buy |
| MA 100 | $296.20 | Buy | $301.62 | Buy |
| MA 200 | $314.21 | Buy | $301.50 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.53 | Neutral |
| Stoch RSI (14) | 92.08 | Sell |
| CCI (20) | 122.11 | Buy |
| Williams %R (14) | -3.10 | Info |
| MACD (12,26,9) | 1.82 | Buy |
| ROC (12) | 7.62 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 96.90 | Sell |
| TRIX (15) | 0.43 | Buy |
| Awesome (5,34) | 31.18 | Buy |
| Ultimate (7,14,28) | 67.95 | Neutral |
| Momentum (10) | 21.94 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 328.68 | Buy |
| ADX (14) | 27.99 | Buy |
| ATR (14) | 4.10 | Info |
Near-term technical picture is bullish, with RSI14 at 70 indicating upside momentum. The asset trades with a 50-day simple moving average around $290.80 and a 200-day simple moving average near $314.97, with a key resistance at $311.26 and a support level at $260.27.
The 30-day price range spans from $280.98 to $344.81, framing current activity within a relatively wide band. Overall sentiment is identified as BULLISH in the near term, consistent with the price environment and moving-average context.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $260.27 | $330.46 | $449.41 | 0% | Neutral | |
| $384.07 | $468.47 | $597.14 | +42% | Bullish | |
| $456.59 | $567.52 | $743.24 | +72% | Bullish | |
| $528.32 | $666.88 | $892.14 | +102% | Bullish | |
| $590.55 | $755.56 | $1,029.10 | +129% | Bullish | |
| $602.15 | $779.86 | $1,079.08 | +136% | Bullish | |
| $685.92 | $898.41 | $1,260.90 | +172% | Bullish | |
| $821.91 | $1,087.91 | $1,546.69 | +229% | Bullish | |
| $934.72 | $1,249.56 | $1,797.82 | +278% | Bullish | |
| $1,056.46 | $1,425.71 | $2,074.17 | +331% | Bullish | |
| $1,575.11 | $2,217.18 | $3,380.69 | +571% | Bullish | |
| $2,811.17 | $4,244.22 | $6,937.70 | +11.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $260.27 | $330.46 | $386.48 | +0.00% |
| August 2026 | $293.07 | $341.88 | $406.56 | +3.46% |
| September 2026 | $299.20 | $350.99 | $421.23 | +2.66% |
| October 2026 | $296.90 | $349.86 | $422.95 | -0.32% |
| November 2026 | $299.98 | $354.82 | $431.50 | +1.42% |
| December 2026 | $309.69 | $367.56 | $449.41 | +3.59% |
Click any year to see its month-by-month ONC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ONC is projected to trade between $260.27 and $449.41, averaging $330.46 — a potential gain of 0% from today's $330.46. A consolidation phase looks the most probable path here.
BeOne Medicines AG's 2027 outlook centres on $468.47, within a $384.07 to $597.14 range. That is up +42% on the projected 2026 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2028, ONC could reach as high as $743.24, with a base case around $567.52 and support toward $456.59 — roughly +72% from $330.46. Buyers look set to stay in control over this stretch.
Expect ONC to range from $528.32 to $892.14 through 2029. The $666.88 average target implies a +102% move from current prices. That is up +18% on the projected 2028 average. Momentum favours further upside here.
The ONC price prediction for 2030 points to an average of $755.56 (low $590.55, high $1,029.10) — a potential gain of +129% on today's $330.46. Buyers look set to stay in control over this stretch.
In 2031, ONC is projected to trade between $602.15 and $1,079.08, averaging $779.86 — a potential gain of +136% from today's $330.46. That is up +3% on the projected 2030 average. Momentum favours further upside here.
BeOne Medicines AG's 2032 outlook centres on $898.41, within a $685.92 to $1,260.90 range. That is up +15% on the projected 2031 average. That marks a +172% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ONC could reach as high as $1,546.69, with a base case around $1,087.91 and support toward $821.91 — roughly +229% from $330.46. Momentum favours further upside here.
Expect ONC to range from $934.72 to $1,797.82 through 2034. The $1,249.56 average target implies a +278% move from current prices. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The ONC price prediction for 2035 points to an average of $1,425.71 (low $1,056.46, high $2,074.17) — a potential gain of +331% on today's $330.46. Momentum favours further upside here.
In 2040, ONC is projected to trade between $1,575.11 and $3,380.69, averaging $2,217.18 — a potential gain of +571% from today's $330.46. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BeOne Medicines AG's 2050 outlook centres on $4,244.22, within a $2,811.17 to $6,937.70 range. That is up +91% on the projected 2040 average. That marks a +11.8x change versus current levels. Momentum favours further upside here.
Investing $1,000 in ONC today (≈ 3.026085 ONC) could be worth
$12,843.37
+$11,843.37 (+1184%) by 2050 · US Dollar
Based on the average projected ONC price of $4,244.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ONCwould be worth at today's price.
$1,000 invested in ONC on Jul 28, 2025 (≈ 3.39547 ONC) would be worth
$1,122.07
+$122.07 (+12.2%) today · 1.12× · US Dollar
Based on a ONC entry price of $294.51 vs. today's $330.46.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $310.58 | $1,064.03 | +6.4% |
| 1 month ago | $279.89 | $1,180.68 | +18.1% |
| 3 months ago | $298.16 | $1,108.33 | +10.8% |
| 6 months ago | $350 | $944.17 | -5.6% |
| 1 year ago | $294.51 | $1,122.07 | +12.2% |
| All time (5.0y) ago | $327.42 | $1,009.28 | +0.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ONC forecast.
Our base-case forecast reaches $660.00 around 2029.
Implied market cap at $660.00: $62.63B
The multi-year forecast shows a bullish trajectory across most future years, with 2026 marked as Neutral, and a sustained bullish outlook from 2027 through 2050. The forecast highlights strong upside potential, with the average price rising from $311.26 in 2026 to $679.81 in 2030 and continuing toward $3,623.04 by 2050, accompanied by substantial ROIs.
Key milestones include 2027 Avg $431.46 with ROI 38.6%, 2028 Avg $531.20 with ROI 70.7%, 2029 Avg $612.79 with ROI 96.9%, and 2030 Avg $679.81 with ROI 118.4%. The forecast extends to 2031 Avg $710.23 (ROI 128.2%) and 2032 Avg $807.64 (ROI 159.5%), continuing to 2033 Avg $967.32 (ROI 210.8%) and beyond, with 2040 Avg $1,945.66 (ROI 525.1%) and 2050 Avg $3,623.04 (ROI 1064%).
These figures reflect a long-run bullish posture, while recognizing that forecasts are estimates and not guaranteed.
Tap a question to reveal the answer.
Avg $679.81, Min $531.10, Max $926.48; ROI 118.4%; Sentiment BULLISH.
Forecast shows bullish sentiment from 2027 onward with rising averages and ROIs; 2026 is Neutral.
Yes—the 2040 max is $2,967.56, which exceeds $2,000.
Current price $311.26; Market cap $32.29B.
Low $280.98; High $344.81.
BeOne Medicines AG Community Discussion
0Share your BeOne Medicines AG price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.